1. Pink Sheet
  2. >>Drug Safety

Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products

 
• By Michael Cipriano

Basically every doctor prescribing any opioid is now covered by the REMS, but training remains voluntary. 

Opioid abuse epidemic concept

The number of opioids encapsulated by the US FDA's risk evaluation and mitigation strategy (REMS) has now increased nearly six-fold, as the agency officially extended it to immediate-release (IR) opioids intended for use in an outpatient setting.

When first created in 2012, the REMS only applied to 62 extended-release (ER) and long-acting (LA) products, but the extension...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 
• By Anabel Costa-Ferreira

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval

 
• By Jessica Merrill

Ultragenyx said talks with the FDA about a path forward after receiving a CRL for UX111 have been productive despite the recent upheaval at the agency.

Prasad 2.0 Brings New Instability Concerns, Questions About Changed Regulatory Philosophy

 
• By Sarah Karlin-Smith

Many agency stakeholders believe Vinay Prasad may be forced to change his regulatory approach at least somewhat after receiving a second chance to lead the US FDA's biologics center.